Quality Measures for Medication Continuity in Long-Term Care Facilities, Using a Structured Panel Process
Identifieur interne : 001501 ( Main/Exploration ); précédent : 001500; suivant : 001502Quality Measures for Medication Continuity in Long-Term Care Facilities, Using a Structured Panel Process
Auteurs : Chaim M. Bell [Canada] ; Stacey S. Brener [Canada] ; Rebecca Comrie [Canada] ; Geoffrey M. Anderson [Canada] ; Susan E. Bronskill [Canada]Source :
- Drugs & aging [ 1170-229X ] ; 2012.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Médicament, Personne âgée.
English descriptors
Abstract
Background: Patient transitions, such as transfers between acute and long-term care (LTC), are times when the likelihood of communication failure between healthcare providers is increased. Employing appropriate health quality indicators helps support improvement efforts. To date, few quality indicators that evaluate the continuity of medication use between acute and LTC facilities have been described. Objective: The aim of the study was to develop quality indicators signalling the potential discontinuation of previously prescribed medications for chronic diseases when residents return to LTC following an acute-care hospitalization. Methods: A literature review for the selection of potential indicators was conducted, followed by a three-step process: (i) initial screening round that rated the indicators; (ii) a 1-day in-person consensus meeting in which the panel refined the parameters regarding the proposed quality indicators; and (iii) a final anonymous survey that assessed consensus among panel members. The study setting was a survey and consensus meeting with national representation, held in Toronto, ON, Canada. A ten-member expert panel with broad geographical and clinical representation participated and was made up of registered nurses, physicians, pharmacists, policy makers and academic researchers. A 75% agreement threshold was required for consensus, as measured on a 9-point Likert-type scale. The panel evaluated quality indicators for effectiveness, relevance and feasibility, using currently available healthcare administrative data. Results: The panel reached consensus on four quality indicators to assess the unintentional discontinuation of medications prescribed to LTC residents for chronic diseases upon return to LTC after an acute-care admission. The selected indicators were (i) HMG-CoA reductase inhibitors (statins) for all indications; (ii) anticoagulants (e.g. warfarin) for the indication of atrial fibrillation; (iii) proton-pump inhibitors for the indication of post-gastrointestinal haemorrhage ; and (iv) thyroxine for all indications. The panel identified three additional treatment groups for future consideration as quality indicators: anti-Parkinson's disease, anti-diabetes and antidepressant medications. Conclusion: A novel set of quality indicators has been developed to evaluate medication continuity between acute and LTC facilities. The adoption and implementation of these indicators in clinical practice can help inform quality improvement efforts at various local and regional levels.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000207
- to stream PascalFrancis, to step Curation: 000A45
- to stream PascalFrancis, to step Checkpoint: 000128
- to stream Main, to step Merge: 001542
- to stream Main, to step Curation: 001501
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Quality Measures for Medication Continuity in Long-Term Care Facilities, Using a Structured Panel Process</title><author><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M." last="Bell">Chaim M. Bell</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>St Michael's Hospital, Keenan Research Centre in the Li Ka Shing Knowledge Institute</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Institute of Health Policy, Management & Evaluation, University of Toronto</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Brener, Stacey S" sort="Brener, Stacey S" uniqKey="Brener S" first="Stacey S." last="Brener">Stacey S. Brener</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>St Michael's Hospital, Keenan Research Centre in the Li Ka Shing Knowledge Institute</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, ON</wicri:noRegion></affiliation></author><author><name sortKey="Comrie, Rebecca" sort="Comrie, Rebecca" uniqKey="Comrie R" first="Rebecca" last="Comrie">Rebecca Comrie</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Health Quality Ontario</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Health Quality Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Anderson, Geoffrey M" sort="Anderson, Geoffrey M" uniqKey="Anderson G" first="Geoffrey M." last="Anderson">Geoffrey M. Anderson</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Institute of Health Policy, Management & Evaluation, University of Toronto</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Bronskill, Susan E" sort="Bronskill, Susan E" uniqKey="Bronskill S" first="Susan E." last="Bronskill">Susan E. Bronskill</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Institute of Health Policy, Management & Evaluation, University of Toronto</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">12-0191856</idno><date when="2012">2012</date><idno type="stanalyst">PASCAL 12-0191856 INIST</idno><idno type="RBID">Pascal:12-0191856</idno><idno type="wicri:Area/PascalFrancis/Corpus">000207</idno><idno type="wicri:Area/PascalFrancis/Curation">000A45</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000128</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000128</idno><idno type="wicri:doubleKey">1170-229X:2012:Bell C:quality:measures:for</idno><idno type="wicri:Area/Main/Merge">001542</idno><idno type="wicri:Area/Main/Curation">001501</idno><idno type="wicri:Area/Main/Exploration">001501</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Quality Measures for Medication Continuity in Long-Term Care Facilities, Using a Structured Panel Process</title><author><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M." last="Bell">Chaim M. Bell</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>St Michael's Hospital, Keenan Research Centre in the Li Ka Shing Knowledge Institute</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, ON</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Institute of Health Policy, Management & Evaluation, University of Toronto</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Brener, Stacey S" sort="Brener, Stacey S" uniqKey="Brener S" first="Stacey S." last="Brener">Stacey S. Brener</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>St Michael's Hospital, Keenan Research Centre in the Li Ka Shing Knowledge Institute</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Toronto, ON</wicri:noRegion></affiliation></author><author><name sortKey="Comrie, Rebecca" sort="Comrie, Rebecca" uniqKey="Comrie R" first="Rebecca" last="Comrie">Rebecca Comrie</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Health Quality Ontario</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>3 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Health Quality Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Anderson, Geoffrey M" sort="Anderson, Geoffrey M" uniqKey="Anderson G" first="Geoffrey M." last="Anderson">Geoffrey M. Anderson</name><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Institute of Health Policy, Management & Evaluation, University of Toronto</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Bronskill, Susan E" sort="Bronskill, Susan E" uniqKey="Bronskill S" first="Susan E." last="Bronskill">Susan E. Bronskill</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institute for Clinical Evaluative Sciences</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Institute for Clinical Evaluative Sciences</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="03"><s1>Institute of Health Policy, Management & Evaluation, University of Toronto</s1><s2>Toronto, ON</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author></analytic><series><title level="j" type="main">Drugs & aging</title><title level="j" type="abbreviated">Drugs aging</title><idno type="ISSN">1170-229X</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Drugs & aging</title><title level="j" type="abbreviated">Drugs aging</title><idno type="ISSN">1170-229X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Drug</term><term>Elderly</term><term>Long term care</term><term>Quality</term><term>Review</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Qualité</term><term>Médicament</term><term>Traitement</term><term>Soins de longue durée</term><term>Article synthèse</term><term>Personne âgée</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term><term>Personne âgée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Patient transitions, such as transfers between acute and long-term care (LTC), are times when the likelihood of communication failure between healthcare providers is increased. Employing appropriate health quality indicators helps support improvement efforts. To date, few quality indicators that evaluate the continuity of medication use between acute and LTC facilities have been described. Objective: The aim of the study was to develop quality indicators signalling the potential discontinuation of previously prescribed medications for chronic diseases when residents return to LTC following an acute-care hospitalization. Methods: A literature review for the selection of potential indicators was conducted, followed by a three-step process: (i) initial screening round that rated the indicators; (ii) a 1-day in-person consensus meeting in which the panel refined the parameters regarding the proposed quality indicators; and (iii) a final anonymous survey that assessed consensus among panel members. The study setting was a survey and consensus meeting with national representation, held in Toronto, ON, Canada. A ten-member expert panel with broad geographical and clinical representation participated and was made up of registered nurses, physicians, pharmacists, policy makers and academic researchers. A 75% agreement threshold was required for consensus, as measured on a 9-point Likert-type scale. The panel evaluated quality indicators for effectiveness, relevance and feasibility, using currently available healthcare administrative data. Results: The panel reached consensus on four quality indicators to assess the unintentional discontinuation of medications prescribed to LTC residents for chronic diseases upon return to LTC after an acute-care admission. The selected indicators were (i) HMG-CoA reductase inhibitors (statins) for all indications; (ii) anticoagulants (e.g. warfarin) for the indication of atrial fibrillation; (iii) proton-pump inhibitors for the indication of post-gastrointestinal haemorrhage ; and (iv) thyroxine for all indications. The panel identified three additional treatment groups for future consideration as quality indicators: anti-Parkinson's disease, anti-diabetes and antidepressant medications. Conclusion: A novel set of quality indicators has been developed to evaluate medication continuity between acute and LTC facilities. The adoption and implementation of these indicators in clinical practice can help inform quality improvement efforts at various local and regional levels.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M." last="Bell">Chaim M. Bell</name></noRegion><name sortKey="Anderson, Geoffrey M" sort="Anderson, Geoffrey M" uniqKey="Anderson G" first="Geoffrey M." last="Anderson">Geoffrey M. Anderson</name><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M." last="Bell">Chaim M. Bell</name><name sortKey="Bell, Chaim M" sort="Bell, Chaim M" uniqKey="Bell C" first="Chaim M." last="Bell">Chaim M. Bell</name><name sortKey="Brener, Stacey S" sort="Brener, Stacey S" uniqKey="Brener S" first="Stacey S." last="Brener">Stacey S. Brener</name><name sortKey="Bronskill, Susan E" sort="Bronskill, Susan E" uniqKey="Bronskill S" first="Susan E." last="Bronskill">Susan E. Bronskill</name><name sortKey="Bronskill, Susan E" sort="Bronskill, Susan E" uniqKey="Bronskill S" first="Susan E." last="Bronskill">Susan E. Bronskill</name><name sortKey="Comrie, Rebecca" sort="Comrie, Rebecca" uniqKey="Comrie R" first="Rebecca" last="Comrie">Rebecca Comrie</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001501 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001501 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:12-0191856
|texte= Quality Measures for Medication Continuity in Long-Term Care Facilities, Using a Structured Panel Process
}}
| This area was generated with Dilib version V0.6.29. |  |